Literature DB >> 9345377

Possible association between multiple sclerosis and the human T cell leukemia virus (HTLV)-related endogenous element, HRES-1.

H B Rasmussen1, A Heltberg, K Christensen, J Clausen.   

Abstract

In the present study we searched for an association between the human endogenous retroviral element HRES-1 and multiple sclerosis (MS). Fragments of this endogenous retrovirus were amplified for subsequent examination by single strand conformational analysis. We did not find HRES-1 markers exclusively linked with MS and only the two already known polymorphisms, which define three alleles of HRES-1, were detected. However, we found a significant difference in the distribution of these alleles between a group of 87 MS patients and a control group of 158 healthy individuals (P = 0.014). There were no differences in the distribution of the HRES-1 allelic forms between MS patients with a relapsing-remitting course and patients with chronic progressive MS. Our results provide evidence of an association between HRES-1 and MS. Possible explanations for this are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9345377     DOI: 10.1177/135245859600200303

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  2 in total

1.  Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/RAB4 expression and mTOR activation.

Authors:  Aparna Godavarthy; Ryan Kelly; John Jimah; Miguel Beckford; Tiffany Caza; David Fernandez; Nick Huang; Manuel Duarte; Joshua Lewis; Hind J Fadel; Eric M Poeschla; Katalin Banki; Andras Perl
Journal:  JCI Insight       Date:  2020-01-16

Review 2.  The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis.

Authors:  Elena Morandi; Radu Tanasescu; Rachael E Tarlinton; Cris S Constantinescu; Weiya Zhang; Christopher Tench; Bruno Gran
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.